HUP0004024A3 - Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof - Google Patents

Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof

Info

Publication number
HUP0004024A3
HUP0004024A3 HU0004024A HUP0004024A HUP0004024A3 HU P0004024 A3 HUP0004024 A3 HU P0004024A3 HU 0004024 A HU0004024 A HU 0004024A HU P0004024 A HUP0004024 A HU P0004024A HU P0004024 A3 HUP0004024 A3 HU P0004024A3
Authority
HU
Hungary
Prior art keywords
azabenzimidazole
preparation
pharmaceutical composition
based compounds
compounds
Prior art date
Application number
HU0004024A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HUP0004024A2 publication Critical patent/HUP0004024A2/hu
Publication of HUP0004024A3 publication Critical patent/HUP0004024A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU0004024A 1997-09-26 1998-09-23 Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof HUP0004024A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6014597P 1997-09-26 1997-09-26
PCT/US1998/019973 WO1999016438A1 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Publications (2)

Publication Number Publication Date
HUP0004024A2 HUP0004024A2 (hu) 2001-04-28
HUP0004024A3 true HUP0004024A3 (en) 2001-10-29

Family

ID=22027657

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004024A HUP0004024A3 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof

Country Status (27)

Country Link
US (2) US6093728A (enExample)
EP (1) EP1017384B1 (enExample)
JP (1) JP2001517699A (enExample)
KR (1) KR100547929B1 (enExample)
CN (1) CN1167420C (enExample)
AR (1) AR017266A1 (enExample)
AT (1) ATE281834T1 (enExample)
AU (1) AU748849B2 (enExample)
BG (1) BG64784B1 (enExample)
BR (1) BR9812682A (enExample)
CA (1) CA2305370C (enExample)
DE (1) DE69827516T2 (enExample)
DK (1) DK1017384T3 (enExample)
ES (1) ES2230719T3 (enExample)
HU (1) HUP0004024A3 (enExample)
IL (4) IL158649A0 (enExample)
NO (1) NO325663B1 (enExample)
NZ (2) NZ503432A (enExample)
PL (1) PL191618B1 (enExample)
PT (1) PT1017384E (enExample)
RU (1) RU2230553C2 (enExample)
SK (1) SK285357B6 (enExample)
TR (1) TR200001546T2 (enExample)
TW (1) TW581815B (enExample)
UA (1) UA72448C2 (enExample)
WO (1) WO1999016438A1 (enExample)
ZA (1) ZA988797B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
BR0208010A (pt) * 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
EP1962892A4 (en) * 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
EP2013207B1 (en) 2006-04-26 2012-04-25 Cancer Research Technology Limited Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
ES2627352T3 (es) * 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
EP2839839B1 (en) * 2007-02-28 2018-01-17 Yeda Research And Development Company Limited Nuclear targeting sequences
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
EP2184285B1 (en) * 2007-08-29 2015-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010025448A2 (en) * 2008-08-29 2010-03-04 University Of South Florida Inhibition of cell proliferation
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2399921B1 (en) 2008-12-01 2015-08-12 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
DK2531502T3 (da) 2010-02-01 2014-05-19 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea og associerede forbindelser og ders anvendelse i terapi
CN103998036B (zh) 2011-10-19 2017-05-31 西格诺药品有限公司 利用tor激酶抑制剂治疗癌症
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
CN104271159B (zh) 2012-02-24 2017-11-28 西格诺药品有限公司 利用tor激酶抑制剂联合治疗来治疗非小细胞肺癌的方法
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3046929B1 (en) 2013-09-17 2019-01-16 Yeda Research and Development Co., Ltd. Erk-derived peptides and uses thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
ES2749103T3 (es) 2014-09-12 2020-03-19 Knopp Biosciences Llc Benzoimidazol-1,2-ilamidas como activadores del canal Kv7
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) * 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
SE422799B (sv) 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
ES473201A1 (es) * 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
ES2064101T3 (es) * 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
JPH06503095A (ja) * 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP0654024A1 (en) * 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
CN1048015C (zh) * 1993-07-06 2000-01-05 美国辉瑞有限公司 双环四氢吡唑并吡啶类化合物
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
CN1278172A (zh) 2000-12-27
US6855723B2 (en) 2005-02-15
CA2305370C (en) 2006-11-28
PL191618B1 (pl) 2006-06-30
ATE281834T1 (de) 2004-11-15
BG64784B1 (bg) 2006-04-28
AU748849B2 (en) 2002-06-13
SK285357B6 (sk) 2006-11-03
TR200001546T2 (tr) 2000-10-23
PL339744A1 (en) 2001-01-02
NZ517808A (en) 2003-07-25
JP2001517699A (ja) 2001-10-09
PT1017384E (pt) 2005-03-31
BR9812682A (pt) 2000-08-22
ZA988797B (en) 1999-12-02
NO325663B1 (no) 2008-07-07
AR017266A1 (es) 2001-09-05
IL135109A (en) 2007-07-04
NO20001555L (no) 2000-03-24
CA2305370A1 (en) 1999-04-08
KR100547929B1 (ko) 2006-02-02
KR20010015623A (ko) 2001-02-26
EP1017384B1 (en) 2004-11-10
IL158649A (en) 2006-12-10
UA72448C2 (en) 2005-03-15
TW581815B (en) 2004-04-01
US20030181480A1 (en) 2003-09-25
BG104356A (en) 2000-12-29
US6093728A (en) 2000-07-25
EP1017384A1 (en) 2000-07-12
HK1032206A1 (en) 2001-07-13
NO20001555D0 (no) 2000-03-24
HUP0004024A2 (hu) 2001-04-28
RU2230553C2 (ru) 2004-06-20
DK1017384T3 (da) 2005-01-31
IL158649A0 (en) 2004-05-12
DE69827516D1 (de) 2004-12-16
ES2230719T3 (es) 2005-05-01
AU9578198A (en) 1999-04-23
WO1999016438A1 (en) 1999-04-08
NZ503432A (en) 2002-11-26
IL135109A0 (en) 2001-05-20
CN1167420C (zh) 2004-09-22
DE69827516T2 (de) 2005-12-01
SK4152000A3 (en) 2002-02-05

Similar Documents

Publication Publication Date Title
IL135920A0 (en) 2-aryl -8-oxodihydropurine derivative, process for the preparation thereof, pharmaceutical composition containing the same and intermediate therefor
HUP0100394A3 (en) 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
HUP9700358A3 (en) New oxazolidinon derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP0003844A3 (en) Novel spiroazabicyclic heterocyclic compounds, process for their preparation, their use and pharmaceutical compositions containing them
IL131415A (en) Anti-inflammatory compounds, processes for their preparation and pharmaceutical compositions comprising them
HUP0001555A3 (en) Tetrahydro-imidazo-naphthyridine derivatives, pharmaceutical compositions thereof and process for their preparation
HUP9603495A2 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol-compounds, pharmaceutical compositions containing the same and process for their preparation
HUP0100431A3 (en) Adamantana derivatives, pharmaceutical compositions comprising them and process for preparing them
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
HUP0102307A3 (en) Bispidine derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0000426A3 (en) Novel benzonaphthyridines, pharmaceutical compositions and use thereof and process for their preparation
HUP0102512A3 (en) Bridged indenopyrrolocarbazoles, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203107A3 (en) Novel spiro compounds, process for their preparation and pharmaceutical compositions containing them
HUP0100488A3 (en) Thienopyrimidines, process for their preparation and pharmaceutical compositions containing them
IL137494A0 (en) Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
HUP0102215A3 (en) Benzoylpyridazines, pharmaceutical compositions containing the same and process for their preparation
HUP0201402A3 (en) Bis-sulfonamides, process for their preparation and pharmaceutical compositions containing them
HUP0003577A3 (en) Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them
HUP9800865A3 (en) Condensed piperidine-derivatives, process for producing them and pharmaceutical compositions containing them
HUP0001093A3 (en) Oxazolidines as 5-ht2a-antagonists, pharmaceutical compositions containing the same and process for their preparation
HUP0001551A3 (en) Improved method for producing thiazolidinediones, thiazolidinediones and pharmaceutical compositions containing the same
HUP0101234A2 (hu) Béta-karbolin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9902784A3 (en) Indan-1-ol compounds, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ZENTARIS GMBH, DE

Free format text: FORMER OWNER(S): ASTA MEDICA AKTIENGESELLSCHAFT, DE; ZENTARIS AG, DE; ZENTARIS GMBH, DE